Pig Kidney Transplants Working in 5 Patients for 8+ Months

After decades of research and false starts, pig kidney transplants are finally working in real patients who desperately needed them.

Massachusetts General Hospital has successfully transplanted genetically engineered pig kidneys into five patients since March 2024. Three of those patients lived for more than eight months without needing dialysis or experiencing organ rejection.

The breakthrough addresses what doctors call the greatest crisis in transplantation today. Thousands of patients wait years for donor kidneys while undergoing grueling dialysis treatments multiple times per week.

Tim Andrews received his pig kidney at age 66 and lived with it for almost nine months before eventually receiving a human donor kidney. The pig kidney kept him off dialysis the entire time, giving him freedom and quality of life he hadn't experienced in years.

The kidneys come from miniature pigs whose organs match human size. Scientists made 10 genetic modifications to each organ, removing three pig proteins that trigger rejection and adding seven human genes for better compatibility. They also deactivated viruses that might infect patients.

Biotech company eGenesis, which developed the technology, plans to expand trials to 33 patients across 10 hospitals starting early next year. If successful, the treatment could receive FDA approval by late 2029.

The Ripple Effect

The impact extends far beyond individual patients. If pig kidneys become widely available, patients could receive transplants when they need them instead of waiting years on dialysis.

Dr. Leonardo Riella, who led the trials, envisions pig kidneys serving as a bridge to keep patients healthy while they wait for human donors. Eventually, these organs might become permanent solutions if long-term safety is confirmed.

The technology is spreading internationally too. A Japanese partner will begin kidney transplant trials in Japan by 2028, bringing hope to patients worldwide.

United Therapeutics and other companies are also working on pig heart transplants using similar techniques. The FDA has already approved small trials for pig hearts, though kidney transplants remain safer since patients can return to dialysis if needed.

What makes this moment different from past xenotransplant attempts is the combination of advanced genetic engineering, improved immunology, and careful patient monitoring. The science has finally caught up to the promise.

Kidney Research UK calls the development exciting while emphasizing the need for continued research to ensure the approach is safer than current alternatives. But for patients like Tim Andrews who lived dialysis-free for nine months, the evidence speaks for itself.

Thousands of patients die each year waiting for donor organs that never come, making every successful pig kidney transplant a victory worth celebrating.